Jitka Soukupova

Dr. Jitka Soukupova


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GBGhali Brahemi
Ghali Brahemi
FKFathima R. Kona
Fathima R. Kona
AFAnnalisa Fiasella
Annalisa Fiasella
DBDaniela Buac
Daniela Buac
JSJitka Soukupova
Jitka Soukupova
AWAndrew Westwell
Andrew Westwell

12 March 2016 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Isabel FabregatIsabel Fabregat
Isabel Fabregat
AMAndrea Malfettone
Andrea Malfettone
JSJitka Soukupova
Jitka Soukupova
The epithelial-mesenchymal transition (EMT) is an example of cellular plasticity, where an epithelial cell acquires a mesenchymal-like phenotype that increases its migratory and invasive properties. Stemness is the ability of stem cells to proliferate in an asymmetric way that allows them to maintain the reservoir of undifferentiated cells with stem cell identity, but also to produce new differentiated cells. Initial works revealed that activation of the EMT program in epithelial cells induces the acquisition of stem cell properties, which in the context of cancer may contribute to the appearance of tumor initiating cells (TIC). However, a number of groups have recently reported that mesenchymal-epithelial transition (MET) is required for efficient metastatic colonization and that EMT may be not necessarily associated with stemness. In this review, we summarize recent findings that extend our knowledge about the crossroads between EMT and stemness and their relevance under physiological or pathological conditions.

1 April 2017 in Cancer Letters
Verified
Journal Article
Closed access
AMAndrea Malfettone
Andrea Malfettone
JSJitka Soukupova
Jitka Soukupova
EBEsther Bertran
Esther Bertran
ECEva Crosas-Molist
Eva Crosas-Molist
RLRaquel Lastra
Raquel Lastra
Isabel FabregatIsabel Fabregat
Isabel Fabregat

15 January 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
AWAlison Wakefield
Alison Wakefield
JSJitka Soukupova
Jitka Soukupova
AMAmelie Montagne
Amelie Montagne
JRJill Ranger
Jill Ranger
RFRhiannon French
Rhiannon French
RCRichard W.E. Clarkson
Richard W.E. Clarkson
Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tumors. Studies in cell lines suggest that its oncogenic effects are mediated through the induction of proliferation and inhibition of cell death, yet its role in endogenous solid tumors has not been established. Here, we address the oncogenic effect of Bcl3 in vivo and describe how this Stat3-responsive oncogene promotes metastasis of ErbB2-positive mammary tumors without affecting primary tumor growth or normal mammary function. Deletion of the Bcl3 gene in ErbB2-positive (MMTV-Neu) mice resulted in a 75% reduction in metastatic tumor burden in the lungs with a 3.6-fold decrease in cell turnover index in these secondary lesions with no significant effect on primary mammary tumor growth, cyclin D1 levels, or caspase-3 activity. Direct inhibition of Bcl3 by siRNA in a transplantation model of an Erbb2-positive mammary tumor cell line confirmed the effect of Bcl3 in malignancy, suggesting that the effect of Bcl3 was intrinsic to the tumor cells. Bcl3 knockdown resulted in a 61% decrease in tumor cell motility and a concomitant increase in the cell migration inhibitors Nme1, Nme2, and Nme3, the GDP dissociation inhibitor Arhgdib, and the metalloprotease inhibitors Timp1 and Timp2. Independent knockdown of Nme1, Nme2, and Arhgdib partially rescued the Bcl3 motility phenotype. These results indicate for the first time a cell-autonomous disease-modifying role for Bcl3 in vivo, affecting metastatic disease progression rather than primary tumor growth. Cancer Res; 73(2); 745–55. ©2012 AACR.

2 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJitka Soukupova
Jitka Soukupova
AMAndrea Malfettone
Andrea Malfettone
PHPetra Hyroššová
Petra Hyroššová
María Isabel Hernández AlvarezMaría Isabel Hernández Alvarez
María Isabel Hernández Alvarez
IPIrene Peñuelas-Haro
Irene Peñuelas-Haro
Isabel FabregatIsabel Fabregat
Isabel Fabregat
Transforming Growth Factor beta (TGF-β) induces tumor cell migration and invasion. However, its role in inducing metabolic reprogramming is poorly understood. Here we analyzed the metabolic profile of hepatocellular carcinoma (HCC) cells that show differences in TGF-β expression. Oxygen consumption rate (OCR), extracellular acidification rate (ECAR), metabolomics and transcriptomics were performed. Results indicated that the switch from an epithelial to a mesenchymal/migratory phenotype in HCC cells is characterized by reduced mitochondrial respiration, without significant differences in glycolytic activity. Concomitantly, enhanced glutamine anaplerosis and biosynthetic use of TCA metabolites were proved through analysis of metabolite levels, as well as metabolic fluxes from U-13C6-Glucose and U-13C5-Glutamine. This correlated with increase in glutaminase 1 (GLS1) expression, whose inhibition reduced cell migration. Experiments where TGF-β function was activated with extracellular TGF-β1 or inhibited through TGF-β receptor I silencing showed that TGF-β induces a switch from oxidative metabolism, coincident with a decrease in OCR and the upregulation of glutamine transporter Solute Carrier Family 7 Member 5 (SLC7A5) and GLS1. TGF-β also regulated the expression of key genes involved in the flux of glycolytic intermediates and fatty acid metabolism. Together, these results indicate that autocrine activation of the TGF-β pathway regulates oxidative metabolism in HCC cells.

7 March 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
BRBhavna Rani
Bhavna Rani
AMAndrea Malfettone
Andrea Malfettone
FDFrancesco Dituri
Francesco Dituri
JSJitka Soukupova
Jitka Soukupova
LLLuigi Lupo
Luigi Lupo
Gianluigi  GiannelliGianluigi Giannelli
Gianluigi Giannelli
Cancer stem cells (CSCs) niche in the tumor microenvironment is responsible for cancer recurrence and therapy failure. To better understand its molecular and biological involvement in hepatocellular carcinoma (HCC) progression, one can design more effective therapies and tailored then to individual patients. While sorafenib is currently the only approved drug for first-line treatment of advanced stage HCC, its role in modulating the CSC niche is estimated to be small. By contrast, transforming growth factor (TGF)-β pathway seems to influence the CSC and thus may impact hallmarks of HCC, such as liver fibrosis, cirrhosis, and tumor progression. Therefore, blocking this pathway may offer an appealing and druggable target. In our study, we have used galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGFβI/ALK5) activation, currently under clinical investigation in HCC patients. Because the drug resistance is mainly mediated by CSCs, we tested the effects of galunisertib on stemness phenotype in HCC cells to determine whether TGF-β signaling modulates CSC niche and drug resistance. Galunisertib modulated the expression of stemness-related genes only in the invasive (HLE and HLF) HCC cells inducing a decreased expression of CD44 and THY1. Furthermore, galunisertib also reduced the stemness-related functions of invasive HCC cells decreasing the formation of colonies, liver spheroids and invasive growth ability. Interestingly, CD44 loss of function mimicked the galunisertib effects on HCC stemness-related functions. Galunisertib treatment also reduced the expression of stemness-related genes in ex vivo human HCC specimens. Our observations are the first evidence that galunisertib effectiveness overcomes stemness-derived aggressiveness via decreased expression CD44 and THY1.